Glaxosmi. Pharma Financials Statement

FINANCIALS

Select Period:

Particulars ( Rupees In Crores.)	Jun-2023	Mar-2023	Dec-2022	Sep-2022	Jun-2022
Gross Sales	761.66	787.45	802.30	916.87	745.10
Excise Duty	--	--	--	--	--
Net Sales	761.66	787.45	802.30	916.87	745.10
Other Operating Income	--	--	--	--	--
Other Income	53.74	38.06	23.42	21.97	30.66
Total Income	815.40	825.51	825.72	938.84	775.76
Total Expenditure	617.78	617.71	584.97	659.94	596.18
PBIDT	197.62	207.80	240.75	278.90	179.58
Interest	0.28	0.65	0.09	0.39	0.68
PBDT	197.34	207.15	240.66	278.51	178.90
Depreciation	16.36	17.18	16.41	16.36	15.82
Minority Interest Before NP	--	--	--	--	--
Tax	53.23	57.30	69.20	73.36	47.27
Deferred Tax	(4.50)	(0.76)	(9.51)	(4.63)	(3.47)
Reported Profit After Tax	132.25	133.43	164.56	193.42	119.28
Minority Interest After NP	--	--	--	--	--
Net Profit after Minority Interest	132.25	133.43	164.56	193.42	119.28
Extra-ordinary Items	12.21	7.26	(7.86)	--	3.05
Adjusted Profit After Extra-ordinary item	120.04	126.17	172.42	193.42	116.23
EPS (Unit Curr.)	7.04	7.41	9.71	11.42	7.04
Book Value (Unit Curr.)	--	--	--	--	--
Dividend (%)	--	--	--	--	--
Equity	169.41	169.41	169.41	169.41	169.41
Public Shareholding (Number)	--	--	--	--	--
Public Shareholding (%)	--	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--	--
PBIDTM(%)	25.95	26.39	30.01	30.42	24.10
PBDTM(%)	25.91	26.31	30.00	30.38	24.01
PATM(%)	17.36	16.95	20.51	21.10	16.01

QuickLinks for Glaxosmithkline Pharmaceuticals Ltd.